Prevention with immunisation still appears out of reach after results fall short of efficacy target
Johnson & Johnson stopped a mid-stage test of its HIV vaccine in southern Africa after the shot showed insufficient ability to protect people from contracting the virus.
The trial, called Imbokodo, showed the vaccine was just 25% effective in preventing HIV infection over a period of two years, short of a goal of 50% efficacy, according to a statement. A similar vaccine developed by the drugmaker will continue being tested in Europe and the Americas in a final-stage study called Mosaico, Paul Stoffels, J&J’s chief scientific officer, said. ..If you have already registered or subscribed, please sign in to continue.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
J&J's HIV vaccine fails in sub-Saharan Africa trialHIV is especially hard to produce a vaccine against, in part because it quickly incorporates itself into its host's DNA.
Read more »
ANC could lose five KwaZulu-Natal municipalities - The Mail & GuardianA registration flop means the party is now pinning its hopes on the electoral court and the Constitutional Court as 27 October approaches.
Read more »
US Pfizer approval is the boost SA vax drive needsProf Salim Abdool Karim believes the thoroughness of the FDA trials will give the vaccine untainted credibility
Read more »
Worrying new variant gaining traction in SA and abroad, says expertScientists fear it could be more transmissible and vaccine-evasive than others
Read more »
Worrying new variant gaining traction in SA and abroad, says expertScientists fear it could be more transmissible and vaccine-evasive than others
Read more »
Meet the non-vaccines that promise to boost Covid-19 immunityBoosters are not the only option and in some cases they may not even be our best
Read more »